Maia Biotechnology Stock Performance
| MAIA Stock | USD 2.00 0.06 3.09% |
MAIA Biotechnology holds a performance score of 13 on a scale of zero to a hundred. The firm secures a Beta (Market Risk) of -0.31, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning MAIA Biotechnology are expected to decrease at a much lower rate. During the bear market, MAIA Biotechnology is likely to outperform the market. Use MAIA Biotechnology standard deviation, treynor ratio, downside variance, as well as the relationship between the total risk alpha and value at risk , to analyze future returns on MAIA Biotechnology.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in MAIA Biotechnology are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite somewhat unsteady forward indicators, MAIA Biotechnology sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Vitoc Vlad of 1800 shares of MAIA Biotechnology at 0.92 subject to Rule 16b-3 | 11/21/2025 |
2 | Acquisition by Vitoc Vlad of 10000 shares of MAIA Biotechnology at 0.9891 subject to Rule 16b-3 | 11/24/2025 |
3 | Acquisition by Smith Stan of 15000 shares of MAIA Biotechnology at 0.98 subject to Rule 16b-3 | 11/25/2025 |
4 | Acquisition by Smith Stan of 4580 shares of MAIA Biotechnology at 1.19 subject to Rule 16b-3 | 12/05/2025 |
5 | MAIAs Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates | 12/11/2025 |
6 | MAIA Biotechnology, Inc. announced that it expects to receive 1.289791 million in funding - marketscreener.com | 12/15/2025 |
7 | MAIA Biotechnology announces 2.25M private placement deal - MSN | 12/17/2025 |
8 | Acquisition by Louie Ngar Yee of 81699 shares of MAIA Biotechnology at 1.36 subject to Rule 16b-3 | 12/22/2025 |
9 | MAIA Biotechnology, Inc. Short Interest Up 144.9 percent in December - MarketBeat | 12/26/2025 |
10 | Acquisition by Chaouki Steven M of 24633 shares of MAIA Biotechnology at 1.53 subject to Rule 16b-3 | 12/31/2025 |
11 | Can MAIA Biotechnology Inc. stock deliver strong annual returns - July 2025 Chart Watch Entry Point Strategy Guides - ulpravda.ru | 01/08/2026 |
12 | MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum | 01/20/2026 |
13 | Acquisition by Smith Stan of 24747 shares of MAIA Biotechnology at 1.8 subject to Rule 16b-3 | 01/22/2026 |
14 | Microsoft Boosts Data Centers, Debuts Maia 200 AI Chip Before Earnings | 01/27/2026 |
15 | Microsoft Highlights Its Growing AI Capabilities in Cloud Services with Maia Chip Launch | 02/03/2026 |
| Begin Period Cash Flow | 7.2 M | |
| Free Cash Flow | -15.7 M |
MAIA Biotechnology Relative Risk vs. Return Landscape
If you would invest 110.00 in MAIA Biotechnology on November 6, 2025 and sell it today you would earn a total of 90.00 from holding MAIA Biotechnology or generate 81.82% return on investment over 90 days. MAIA Biotechnology is currently generating 1.3137% in daily expected returns and assumes 8.0111% risk (volatility on return distribution) over the 90 days horizon. In different words, 71% of stocks are less volatile than MAIA, and 74% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
MAIA Biotechnology Target Price Odds to finish over Current Price
The tendency of MAIA Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.00 | 90 days | 2.00 | about 13.97 |
Based on a normal probability distribution, the odds of MAIA Biotechnology to move above the current price in 90 days from now is about 13.97 (This MAIA Biotechnology probability density function shows the probability of MAIA Stock to fall within a particular range of prices over 90 days) .
MAIA Biotechnology Price Density |
| Price |
Predictive Modules for MAIA Biotechnology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MAIA Biotechnology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.MAIA Biotechnology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. MAIA Biotechnology is not an exception. The market had few large corrections towards the MAIA Biotechnology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MAIA Biotechnology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MAIA Biotechnology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.95 | |
β | Beta against Dow Jones | -0.31 | |
σ | Overall volatility | 0.49 | |
Ir | Information ratio | 0.12 |
MAIA Biotechnology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MAIA Biotechnology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MAIA Biotechnology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MAIA Biotechnology is way too risky over 90 days horizon | |
| MAIA Biotechnology appears to be risky and price may revert if volatility continues | |
| MAIA Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (15.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Microsoft Highlights Its Growing AI Capabilities in Cloud Services with Maia Chip Launch |
MAIA Biotechnology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MAIA Stock often depends not only on the future outlook of the current and potential MAIA Biotechnology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MAIA Biotechnology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 22.2 M | |
| Cash And Short Term Investments | 9.6 M | |
| Shares Float | 32.1 M |
MAIA Biotechnology Fundamentals Growth
MAIA Stock prices reflect investors' perceptions of the future prospects and financial health of MAIA Biotechnology, and MAIA Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MAIA Stock performance.
| Return On Equity | -26.91 | ||||
| Return On Asset | -1.48 | ||||
| Current Valuation | 77.62 M | ||||
| Shares Outstanding | 37.03 M | ||||
| Price To Book | 2,124 X | ||||
| EBITDA | (23.25 M) | ||||
| Net Income | (23.25 M) | ||||
| Cash And Equivalents | 8.15 M | ||||
| Cash Per Share | 0.75 X | ||||
| Total Debt | 6.52 M | ||||
| Current Ratio | 2.78 X | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (15.7 M) | ||||
| Earnings Per Share | (0.74) X | ||||
| Market Capitalization | 71.84 M | ||||
| Total Asset | 10.16 M | ||||
| Retained Earnings | (87.23 M) | ||||
| Working Capital | 6.32 M | ||||
About MAIA Biotechnology Performance
By analyzing MAIA Biotechnology's fundamental ratios, stakeholders can gain valuable insights into MAIA Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MAIA Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MAIA Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.06) | (2.16) | |
| Return On Capital Employed | (3.08) | (3.24) | |
| Return On Assets | (2.06) | (2.16) | |
| Return On Equity | (7.36) | (6.99) |
Things to note about MAIA Biotechnology performance evaluation
Checking the ongoing alerts about MAIA Biotechnology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MAIA Biotechnology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MAIA Biotechnology is way too risky over 90 days horizon | |
| MAIA Biotechnology appears to be risky and price may revert if volatility continues | |
| MAIA Biotechnology has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.25 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (15.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 20.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from finance.yahoo.com: Microsoft Highlights Its Growing AI Capabilities in Cloud Services with Maia Chip Launch |
- Analyzing MAIA Biotechnology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MAIA Biotechnology's stock is overvalued or undervalued compared to its peers.
- Examining MAIA Biotechnology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MAIA Biotechnology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MAIA Biotechnology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MAIA Biotechnology's stock. These opinions can provide insight into MAIA Biotechnology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for MAIA Stock analysis
When running MAIA Biotechnology's price analysis, check to measure MAIA Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MAIA Biotechnology is operating at the current time. Most of MAIA Biotechnology's value examination focuses on studying past and present price action to predict the probability of MAIA Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MAIA Biotechnology's price. Additionally, you may evaluate how the addition of MAIA Biotechnology to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |